

CITATION REPORT

List of articles citing

Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

DOI: 10.1517/17425255.2.4.609

Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 609-17.

Source: <https://exaly.com/paper-pdf/39617668/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	Lower urinary tract symptoms (LUTS) and bladder afferent activity. <i>Neurourology and Urodynamics</i> , 2007 , 26, 908-13	2.3	54
16	Tadalafil as an in vitro sperm motility stimulant. <i>Andrologia</i> , 2007 , 39, 12-5	2.4	16
15	Influence of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate on erectile function: a short-term follow-up study. <i>Journal of Sexual Medicine</i> , 2007 , 4, 1701-7	1.1	33
14	Is the current practice providing an integrated approach to the management of LUTS and ED in primary care? An audit and literature review. <i>Journal of Sexual Medicine</i> , 2007 , 4, 1713-25	1.1	20
13	[Control mechanisms of tonus of smooth muscle of the prostate and their potential significance for pharmacotherapy of benign prostatic syndrome]. <i>Der Urologe</i> , 2007 , 46, 1187-8		
12	Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. <i>Journal of Sexual Medicine</i> , 2008 , 5, 2502-18	1.1	37
11	Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. <i>Urology</i> , 2008 , 71, 526-30	1.6	64
10	Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. <i>Annals of Pharmacotherapy</i> , 2008 , 42, 111-5	2.9	15
9	Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. <i>Journal of Sexual Medicine</i> , 2009 , 6, 544-52	1.1	89
8	Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 139-148	6.4	76
7	PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. <i>Current Bladder Dysfunction Reports</i> , 2013 , 8, 150-159	0.4	12
6	Sexual Dysfunction and Fertility in Neurogenic Lower Urinary Tract Dysfunction. 2019 , 457-478		
5	Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease. <i>Mechanisms of Ageing and Development</i> , 2020 , 190, 111311	5.6	4
4	A narrative review of the management of benign prostatic hyperplasia in patients undergoing penile prosthesis surgery. <i>Translational Andrology and Urology</i> , 2021 , 10, 2695-2704	2.3	0
3	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α -Blockers and 5-Alpha Reductase Inhibitors. <i>Uro</i> , 2021 , 1, 82-98		
2	Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. <i>Medical Science Monitor</i> , 2020 , 26, e923179	3.2	1
1	Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 139-48	6.4	29

